|33.70||+0.6000||+1.81%||Vol 842.28K||1Y Perf 44.14%|
|Sep 15th, 2021 16:00 DELAYED|
|- -%||- -|
|Target Price||47.00||Analyst Rating||Strong Buy 1.10|
|Potential %||39.47||Finscreener Ranking||★★★★ 54.06|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★+ 53.31|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★ 61.09|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||96.84||Earnings Rating||Strong Sell|
|Market Cap||2.81B||Earnings Date||3rd Nov 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||3rd Nov 2021|
|Estimated EPS Next Report||-0.77|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.17M|
|Avg. Monthly Volume||895.89K|
|Avg. Quarterly Volume||1.85M|
Cytokinetics Incorporated (NASDAQ: CYTK) stock closed at 33.7 per share at the end of the most recent trading day (a 1.81% change compared to the prior day closing price) with a volume of 853.02K shares and market capitalization of 2.81B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 156 people. Cytokinetics Incorporated CEO is Robert I. Blum.
The one-year performance of Cytokinetics Incorporated stock is 44.14%, while year-to-date (YTD) performance is 62.18%. CYTK stock has a five-year performance of 290.05%. Its 52-week range is between 14.71 and 34.32, which gives CYTK stock a 52-week price range ratio of 96.84%
Cytokinetics Incorporated currently has a PE ratio of -13.40, a price-to-book (PB) ratio of 149.51, a price-to-sale (PS) ratio of 45.48, a price to cashflow ratio of 277.60, a PEG ratio of 2.32, a ROA of -38.48%, a ROC of -53.61% and a ROE of 472.68%. The company’s profit margin is -%, its EBITDA margin is -208.70%, and its revenue ttm is $57.80 Million , which makes it $0.69 revenue per share.
Of the last four earnings reports from Cytokinetics Incorporated, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.77 for the next earnings report. Cytokinetics Incorporated’s next earnings report date is 03rd Nov 2021.
The consensus rating of Wall Street analysts for Cytokinetics Incorporated is Strong Buy (1.1), with a target price of $47, which is +39.47% compared to the current price. The earnings rating for Cytokinetics Incorporated stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cytokinetics Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cytokinetics Incorporated has a Buy technical analysis rating based on Technical Indicators (ADX : 8.65, ATR14 : 1.67, CCI20 : 108.92, Chaikin Money Flow : -0.05, MACD : 0.71, Money Flow Index : 55.16, ROC : 1.26, RSI : 62.06, STOCH (14,3) : 88.12, STOCH RSI : 1.00, UO : 51.64, Williams %R : -11.88), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cytokinetics Incorporated in the last 12-months were: B. Lynne Parshall (Option Excercise at a value of $211 698), B. Lynne Parshall (Sold 30 311 shares of value $909 330 ), Ching Jaw (Option Excercise at a value of $275 700), Ching Jaw (Sold 27 500 shares of value $825 000 ), David W. Cragg (Option Excercise at a value of $408 481), David W. Cragg (Sold 47 957 shares of value $1 233 203 ), Edward M. Kaye (Option Excercise at a value of $152 200), Edward M. Kaye (Sold 20 000 shares of value $600 000 ), Fady Ibraham Malik (Option Excercise at a value of $117 750), Fady Ibraham Malik (Sold 31 673 shares of value $688 331 ), John T. Henderson (Option Excercise at a value of $49 853), John T. Henderson (Sold 4 591 shares of value $112 259 ), Leonard Patrick Gage (Option Excercise at a value of $228 792), Leonard Patrick Gage (Sold 28 055 shares of value $625 878 ), Robert I. Blum (Option Excercise at a value of $1 581 657), Robert I. Blum (Sold 130 000 shares of value $2 876 105 ), Sandford Drexel Smith (Option Excercise at a value of $516 950), Sandford Drexel Smith (Sold 55 936 shares of value $1 489 825 ), Santo J. Costa (Option Excercise at a value of $141 750), Santo J. Costa (Sold 15 000 shares of value $450 000 )
Thu, 12 Aug 2021 20:05 GMT Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Zealand Pharma (ZEAL)- TipRanks. All rights reserved.
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.